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ABSTRACT 
Objective: Rimonabant, the first selective cannabinoid type 1 (CBB1) receptor blocker, has been shown to 
improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis assessed the impact of 
rimonabant on blood pressure in the pooled population from four large trials with similar design - the 
Rimonabant-In-Obesity (RIO) programme. 
Methods: RIO-Europe (n = 1507) and RIO-North America (n= 3040) recruited overweight/obese patients, and 
RIO-Lipids (n = 1033) and RIO-Diabetes (n = 1045) recruited overweight/obese patients with untreated 
dyslipidaemia or type 2 diabetes, respectively. At study entry (screening), 37.2% (n = 2463) of patients had 
hypertension, 71.4% (n = 1757) of whom were taking an antihypertensive treatment. 
Results: After 1 year of treatment, mean change in systolic blood pressure (SBP) from baseline was -0.8 mmHg 
for rimonabant 20 mg versus +0.3 mmHg for placebo (P= 0.007); diastolic blood pressure (DBP) decreased by -
0.8 versus -0.3 mmHg (P = 0.029) respectively. In the subgroup of patients with high blood pressure at baseline, 
SBP change was -7.5 mmHg for rimonabant 20 mg versus -4.7 mmHg for placebo (P= 0.005); DBP change was 
-5.2 versus -3.0 mmHg (P<0.001). Reductions were more pronounced in patients with dyslipidaemia and type 2 
diabetes. There was no effect of rimonabant 20 mg on blood pressure beyond that expected from weight loss 
alone. Overall, there was a similar incidence of adverse events (AEs) at 1 year in the placebo (81.8%) and 
rimonabant 20 mg (86.0%). The most common AEs occurring with rimonabant were nausea, dizziness, 
arthralgia and diarrhoea. A slightly higher proportion of patients in the rimonabant 20 mg group discontinued as 
a result of AEs (13.8%) versus placebo (7.2%). 
Conclusions: Rimonabant 20 mg led to modest, but significant SBP and DBP reductions in overweight/obese 
patients. The effect of rimonabant on blood pressure appears to be mediated by weight loss. 
Keywords: blood pressure, diabetes, dyslipidaemia, overweight/obesity, rimonabant, risk factor 
Abbreviations: ANCOVA, analysis of co-variance; BMI, body mass index; CBB1, cannabinoid type 1 receptor; 
CHD, coronary heart disease; DBP, diastolic blood pressure; ECS, endocannabinoid system; HDL-C, high 
density lipoprotein-cholesterol; ITT, intention to treat; RIO, Rimonabant in Obesity; SBP, systolic blood 
pressure; SHR, spontaneously hypertensive rats; TG, triglycerides 
 
INTRODUCTION 
Although the awareness and treatment of hypertension has increased in recent years, blood pressure control 
remains suboptimal with only 36.8% of hypertensive patients achieving treatment goals [1]. Hypertension is a 
key risk factor for cardiovascular disease, contributing to the increased prevalence of cardiovascular events [2]; 
reducing blood pressure by an average of 12/6 mmHg has been shown to reduce stroke by 40% and coronary 
heart disease by 20% [3]. The absolute risk reduction will be greatest in those at highest risk, such as patients 
with type 2 diabetes. Results from the United Kingdom Prospective Diabetes Study (UKPDS) indicated that a 
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reduction of elevated blood pressure might decrease cardiovascular disease morbidity and mortality even more 
than reduction of hyperglycaemia [4]. 
The link between obesity (particularly abdominal obesity) and hypertension and other cardiometabolic risk 
factors is well established [5-9]. Indeed, data from the Framingham Heart Study estimate that 75 and 65% of the 
cases of hypertension in men and women, respectively, are directly attributable to overweight and obesity [10]. 
The attributable risk of hypertension induced by abdominal obesity has been estimated to range from 21 to 57%, 
depending on gender and ethnicity [11]. Body weight change  itself is a potent modulator of hypertension risk: in 
the Nurses Health Study after adjusting for body mass index, weight gain in adulthood of as little as 2.1-4.9 kg 
increased the risk of hypertension by 29%, whereas weight loss of 5 kg was associated with a 15% reduction in 
hypertension risk [12]. A meta-analysis of randomized, controlled trials showed that weight loss is important for 
the prevention and treatment of hypertension: blood pressure reductions were -1.05 mmHg for SBP and -0.92 
mmHg for DBP when expressed per kilogram of weight loss [13]. While short-term interventions to produce 
weight loss effectively lower blood pressure, long-term maintenance of a reduced body weight is a difficult 
objective to achieve. Pharmacotherapy can facilitate sustained weight loss and can benefit some patients; 
however, some weight-loss agents may increase or prevent the weight-loss-induced reduction in blood pressure 
[14]. 
The recently discovered endocannabinoid system (ECS) plays a role in energy balance, and glucose and lipid 
metabolism through central and peripheral actions [15,16]. Recently, an association between the overactiva-tion 
of the ECS, the abdominal obesity phenotype characterized by high visceral or intra-abdominal fat, and the 
different cardiometabolic risk factors has been described [17-19]. While this association with abdominal obesity 
suggests that the overactive ECS is a potential target for addressing blood pressure, current evidence indicates 
that in rodent models of hypertension, inhibition of the overactive ECS using cannabinoid type 1 receptor (CB1) 
blockade evoked further sustained increases in blood pressure [20]. 
Rimonabant, the first selective CBB1 receptor blocker, has been shown to improve multiple cardiometabolic risk 
factors, such as abdominal obesity, dyslipidaemia, glycae-mic control and insulin resistance in overweight/obese 
patients [21-24]. About 50% of the effects of rimonabant on lipid and glycaemic variables has been shown to be 
independent of weight loss and may reflect direct metabolic effects of CB1B  blockade in peripheral tissues [15-
17,25]. 
The aim of this exploratory analysis was to investigate a possible effect on blood pressure of CB1 blockade by 
assessing the impact of rimonabant on blood pressure in overweight/obese patients with dyslipidaemia, type 2 
diabetes and high blood pressure (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg in patients with type 2 diabetes 
and SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg in patients without diabetes) using pooled and individual study 
data from the four large Rimonabant-In-Obesity (RIO) multicentre, randomized controlled trials. 
METHODS 
Overview of the RIO programme 
The RIO (Rimonabant in Obesity and Related Metabolic Disorders)  trial  programme  included  four  Phase  III, 
multinational, multicentre, randomized, double-blind, placebo-controlled, fixed-dose studies in overweight/ 
obese patients [body mass index (BMI) >27kg/m²] [21-24]. RIO-North America (n = 3040) and RIO-Europe (n= 
1507) included patients with or without dyslipidaemia, RIO-Lipids (n =1033; BMI 27-40 kg/m2) included 
patients with untreated dyslipidaemia, and RIO-Diabetes (n =1040; BMI 27-40 kg/m2) included patients with 
type 2 diabetes receiving metformin or sulfonylureas. All studies included patients with or without hypertension. 
Study design 
The study design for Year 1 was identical in the four studies. The protocol and patient inclusion/exclusion 
criteria have been described in detail [21-24]. Briefly, after a 2-week screening period a mildly hypocaloric diet 
(600 kcal/day deficit) was prescribed for all patients, starting with a 4-week single-blind placebo run-in period. 
Thereafter, patients had their baseline evaluation and were then randomized to placebo, rimonabant 5 mg/day or 
rimonabant 20 mg/day while continuing the hypocaloric diet (600 kcal reduction) and were encouraged to 
increase physical activity. Patients were allocated to treatment using an Interactive Voice Responding System 
(IVRS) (central randomization) ensuring that the study participants, treatment providers and sponsor did not 
have access to the treatment assignments for each randomization code. The primary endpoint of the trials was 
mean change in body weight from baseline at 1 year, with secondary endpoints including a range of 
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cardiometabolic risk factors, such as waist circumference, haemoglobin Alc (HbAlc), high-density lipoprotein 
cholesterol (HDL-C) and triglyceride (TG) levels, plasma glucose and insulin levels, and blood pressure. 
Specifically, supine systolic (SBP) and diastolic blood pressure (DBP) were exploratory secondary endpoints in 
the RIO trials in addition to being a measure of clinical safety. 
Blood pressure was measured in agreement with the existing Committee for Proprietary Medicinal Products 
(CPMP) guidelines [26]. Readings were taken in the supine position using a calibrated mercury 
sphygmomanometer and an appropriately sized cuff. At the screening visit, two consecutive readings separated 
by 2 min were taken in both arms. The arm with the higher pressure was determined and this arm was used for 
the measurement of blood pressure throughout the study. Two readings of supine blood pressure separated by 2 
min were then recorded at every patient visit under standardized conditions, approximately at the same time each 
day, on the same arm, by the same person and with the same apparatus. Hypertension was defined in the protocol 
as SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg in patients with type 2 diabetes, and  SBP ≥ 140 mmHg  and/or  
DBP ≥ 90 mmHg in patients without diabetes, or the presence of antihypertensive therapy if blood pressure was 
below these limits; patient hypertension status was recorded at the screening visit. This exploratory analysis used 
the above SBP and DBP cut-off points to identify patients with high blood pressure at baseline. 
The RIO study protocols were approved by the institutional review board/ethics committee for each participating 
centre. The study was conducted in full compliance with the Declaration of Helsinki. 
Statistical analysis 
The effects of rimonabant 5 and 20 mg/day treatment on blood pressure over 1 year were evaluated in the four 
individual studies and in the pooled studies data. In the individual trials, the 5 mg dose did not consistently 
produce clinically relevant improvements in body weight or lipid and glycaemic parameters [21-24]. 
Accordingly, only the rimonabant 20 mg dose (the dose approved commercially in Europe) and placebo were 
presented in these analyses. The effects of treatment on the change from baseline in blood pressure and the other 
efficacy endpoints were assessed using analysis of variance. Placebo-adjusted effects of rimonabant were 
assessed as the least-squares (LS) mean difference. Blood pressure changes were also analysed in patients with 
high blood pressure at baseline from the following populations of the studies: pooled across the four RIO trials; 
those with untreated dyslipidaemia [21]; and those with type 2 diabetes [23]. All analyses were applied to the 
modified intent-to-treat population, defined as all patients who were randomized, exposed to at least one dose of 
study drug and had at least one post-baseline assessment. Missing data at study endpoint were imputed using the 
last observation carried forward method. 
Differences between treatment arms in changes in anti-hypertension medications were analysed using a chi-
squared test to compare the frequency distribution of patients in each treatment group who had an upward 
adjustment, downward adjustment, no change or change to another drug due to insufficient efficacy, or another 
reason during the treatment period. 
An analysis of the direct effect of rimonabant on blood pressure was conducted in order to provide a quantitative 
assessment of the degree to which blood pressure changes at 1 year might be mediated by direct effects of the 
treatment. The model was based on a standard regression method in which body weight loss was introduced as a 
post-randomization covariate [analysis of covariance (ANCOVA)]. To assess any weight-independent effect of 
rimonabant on a given variable, the portion of the effect of rimonabant that was due to body weight change was 
removed from the total effect on the variable. The ANCOVA model introduced treatment group and body weight 
change as a covariate. The methodology for this analysis has also been described elsewhere [21,22]. 
RESULTS 
The pooled 1-year intent-to-treat population consisted of 1602 patients and 2503 patients randomized to placebo 
and rimonabant 20 mg, respectively. Characteristics of the patients in each of the individual RIO studies have 
been published previously [21-24]; all four studies pooled are summarized in Table 1. Overall, the RIO studies 
represent an at-risk population of overweight/ obese patients with an elevated waist circumference (86-97%) and 
a high rate of cardiometabolic risk factors. In total, 37% of the pooled population had previously diagnosed 
hypertension, comprising 61% of patients in RIO-Diabetes (BP ≥ 130/85 mmHg) and 27% of RIO-Lipids and 
30-41% of RIO-North America and RIO-Europe (BP ≥ 140/90 mmHg). Of the patients previously diagnosed 
with hypertension, 71% of the pooled patients were receiving antihypertensive medication. The percentage of the 
overall patient population from the four individual RIO trials receiving antihypertensive medications were: 
angiotensin-converting enzyme inhibitors 11.6-12.7%; angiotensin II receptor blockers 5.2-6.2%; beta-
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adrenergic receptor blockers 8.4-8.5%; calcium-channel blockers 6.3-6.5%; and diuretics 7.7-9.9%. During the 
treatment period most patients had no changes in antihypertensive medications (approximately 94% of patients) 
and the distribution of changes in antihypertensive medication was not significantly different in the two 
treatment arms. In the placebo and rimonabant 20 mg groups, 3.8 versus 2.7% required upward dose changes; 
1.3 versus 2.0% required downward dose changes; and 0.4 versus 0.3% of patients had medication changes due 
to insufficient efficacy over 1 year. 
Table 1   Patient overall demographic and baseline characteristics 
 Pooled studiesa (n = 6625) 
Age (years) 47.1  (11.6) 
Gender (%) 
     Male 27.4 
     Female 72.6 
Race (%) 
     Caucasian 88.9 
     Black 7.1 
     Other 4.0 
Weight (kg) 100.8 (19.5) 
Waist circumference (cm) 106.8 (13.9) 
Body mass index (kg/m2) 36.0 (5.8) 
Hypertension (%)b 37.2 
     Drug treatment if hypertensive (%) 71.4 
Abdominal obesity (%) 
     Male (waist circumference > 102 cm) 85.5 
     Female (waist circumference >88cm) 90.5 
Dyslipidaemia (%)c 66.9 
     Drug treatment if dyslipidaemic (%) 17.8 
Type 2 diabetes (%)d 15.8 
Metabolic syndrome (%)e 46.5 
Values are mean (SD) unless otherwise noted. aPooled group comprises patients undergoing 1 year of treatment in the RIO-North America, 
RIO-Europe, RIO-Lipids and RIO-Diabetes studies. bHypertension: defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic 
blood pressure (DBP) ≥ 90 mmHg in patients without type 2 diabetes, and SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg in patients with type 2 
diabetes, or antihypertension treatment, as per protocol. cDyslipidaemia: defined as triglyceride levels ≥ 1.69 mmol (150mg/dl) and/or total 
cholesterol/high-density lipoprotein cholesterol (HDL-C) ratio > 4.5 in women or > 5 in men, as per protocol. dType 2 diabetes: haemoglobin 
A1c 6.5-10.0% and fasting glucose concentration 5.55-15.04 mmol/l, as per protocol. ePercentage of patients meeting the criteria for 
metabolic syndrome (ATP III), defined as at least three of the following: abdominal obesity (waist circumference) > 102 cm for men and > 
88 cm for women; triglycerides level ≥ 1.695 mmol (150mg/dl); HDL-C level < 1.036 mmol (40mg/dl) for men and < 1.295 mmol (50mg/dl) 
forwomen; SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; and fasting glucose level > 6.1 mmol (110mg/dl). 
 
Overall pooled population (four RIO studies) 
In the overall population during the run-in period (before randomization to placebo or rimonabant treatment), 
there was a substantial mean (SD) decrease in SBP [-2.9 (11.3) mmHg] and DBP [-1.3 (7.8) mmHg] (Table 2a). 
This decrease was even more marked in those patients with high blood pressure at the beginning of the placebo 
run-in period (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg in patients with type 2 diabetes and SBP ≥ 140 mmHg 
and/or DBP ≥ 90 mmHg in patients without diabetes): SBP -7.4 (11.9) mmHg and DBP -3.7 (8.0) mmHg (Table 
2a). During the run-in period, body weight and waist circumference decreased by -1.8 (2.1) kg and -1.9 (3.8) cm, 
respectively, in the overall pooled population, and by -2.0 (2.1) kg and -1.8 (3.6) cm, respectively, in the 
subgroup with high blood pressure at baseline. 
The effect of 1 year of treatment with rimonabant 20 mg/day on blood pressure in the pooled ITT population is 
shown in Table 2b and Fig. 1. In the overall population (Fig. la), changes in SBP and DBP from baseline were 
statistically significant between rimonabant 20 mg/day and placebo groups (P = 0.007 and P = 0.029, versus 
placebo, respectively). In patients with high blood pressure at baseline (Fig. lb), mean changes in SBP and DBP 
were more pronounced, with significant reductions in SBP and DBP in the rimonabant 20 mg/day group versus 
placebo (P = 0.005 and P < 0.001, respectively). 
Body weight loss and the reductions in waist circumference at 1 year were also significantly greater in the 
rimonabant 20 mg group compared with placebo. In the overall pooled ITT population receiving rimonabant 20 
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mg/day, mean weight loss from baseline at 1 year was -6.3 (6.8) kg (P < 0.001 versus placebo). A similar 
reduction in body weight was reported in patients with high blood pressure at baseline: -6.6 (6.7) kg (P < 0.001 
versus placebo). Rimonabant 20 mg/day also evoked similar reductions in waist circumference in the pooled ITT 
patients [-6.2 (7.0) cm] and in those with high blood pressure at baseline [-6.3 (7.2) cm], both P < 0.001 versus 
placebo. As previously reported in the individual RIO studies [21-24], significantly greater improvements were 
also observed in the rimonabant 20 mg groups compared with placebo in HbAlc, fasting plasma glucose and 
insulin levels, HDL-C and TG. 
Relationship between blood pressure changes and weight loss 
Regression lines from the ANGOVA model showing the changes in SBP or DBP regressed on the change in 
body weight from baseline in the overall population and in patients with high blood pressure for the rimonabant 
20mg/day and placebo groups were virtually identical (Fig. 2a and b). As expected, there was a strong linear 
relationship between degree of weight loss and blood pressure reductions; however, this relationship was similar 
in the two treatment arms. After adjusting the observed changes in blood pressure for weight changes in the 
analysis of covariance, the residual treatment effect on blood pressure was not significant. Thus, the effect of 
rimonabant 20mg/day is consistent with that seen for placebo in patients matched for the same degree of weight 
loss. This suggests that rimonabant 20mg/day does not have an additional effect on blood pressure beyond that 
attributable to weight loss. 
 
Table 2   Change in blood pressure during run-in (a) and after 1 year (b) (four pooled studiesa) 
(a) Change in blood pressure during placebo run-in period at screening (4 weeks; ITT population) 
 Overall population  
n = 6625 
High blood pressureb at screening  
n = 1987 
Supine SBP (mmHg) 
   Start of run-in 127.5 (13.9) 142.5 (9.5) 
   End of run-in 124.6 (13.5) 135.1  (12.3) 
   Change -2.9 (11.3) -7.4 (11.9) 
Supine DBP (mmHg) 
   Start of run-in 79.8 (8.7) 87.0 (7.8) 
   End of run-in 78.5 (8.3) 83.3 (7.9) 
   Change -1.3 (7.8) -3.7 (8.0) 
(b) Change in blood pressure after 1 year (ITT population, LOCF) 




n = 1570 
Rimonabant 20 mg 
n = 2466 
Placebo 
n = 396 
Rimonabant 20 mg   
n = 526 
Supine SBP (mmHg) 
   Mean baseline (SD) 124.7 (13.4) 124.6 (13.4) 140.7 (9.3) 141.7 (9.8) 
   Year 1 125.0 (13.8) 123.8 (13.6) 136.0 (13.5) 134.3 (13.0) 
   Mean change from baseline (SD) 0.3 (1 2.0) -0.8 (12.4) -4.7 (13.2) -7.5 (13.2) 
   LS Mean change versus placebo (SE) - -1.1  (0.4) - -2.5 (0.9) 
   P value (20 mg versus placebo)  (P = 0.007)  (P = 0.005) 
Supine DBP (mmHg) 
   Mean baseline (SD) 78.6 (8.1) 78.4 (8.3) 85.5 (7.4) 86.5 (7.6) 
   Year 1 78.3 (8.4) 77.5 (8.2) 82.5 (8.7) 81.3 (8.0) 
   Mean change from baseline (SD) -0.3 (8.2) -0.8 (8.4) -3.0 (8.8) -5.2 (8.1) 
   LS Mean change versus placebo (SE) - -0.6 (0.3) - -2.0 (0.6) 
   P value (20 mg versus placebo)  (P = 0.029)  (P< 0.001) 
DBP, diastolic blood pressure; ITT, intention-to-treat; LOCF, last observation carried forward; LS, least squares; SBP, systolic blood 
pressure. aPooled group comprises patients undergoing the first year of treatment in the RIO-North America, RIO-Europe, RIO-Lipids and 
RIO-Diabetes studies. bBP ≥ 140/90 mmHg (RIO-North America, RIO-Europe and RIO-Lipids) or ≥ 130/85 mmHg (RIO-Diabetes). 
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(a) Systolic blood pressure (SBP) (left panel) and diastolic blood pressure (DBP) (right panel) over 1 year in the overall intention-to-treat 
(ITT) population from the four pooled Rimonabant In Obesity (RIO) studies. Data are means (SEM) (P versus placebo), (b) SBP (left panel) 
and DBP (right panel) over 1 year in patients with high blood pressure at baseline in the four pooled RIO studies (high blood pressure 
defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg in patients without type 2 diabetes and SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg in 
patients with type 2 diabetes). LOCF (last observation carried forward): mean (SD). Dotted lines, placebo; solid lines rimonabant 20mg. 
 
Patients with type 2 diabetes (RIO-Diabetes) 
Of the patients with type 2 diabetes previously diagnosed with hypertension at screening in the RIO-Diabetes 
trial, 93% of these were receiving antihypertensive drug treatment, compared with only 55-69% in the other RIO 
studies. In the overall patient population from the RIO-Diabetes trial, changes in SBP and DBP overall were 
small but greater in the rimonabant 20 mg group compared with placebo (P = 0.02 and P = 0.06 versus placebo, 
respectively; Fig. 3a). In patients with both type 2 diabetes and high blood pressure (SBP ≥ 130 mmHg and/or 
DBP ≥ 85 mmHg) at baseline, mean reductions from baseline in both SBP and DBP were more pronounced than 
in the overall trial population and were significantly greater in the rimonabant 20mg/day group than the placebo 
group (P = 0.013 and P = 0.024 versus placebo) (Fig. 3b). 
Patients with untreated dyslipidaemia (RIO-Lipids) 
In patients with untreated atherogenic dyslipidaemia, the mean reductions from baseline in SBP and DBP were 
significantly greater in the rimonabant 20mg/day group than the placebo group CP<0.05), for both the overall 
population (Fig. 4a) and for patients with high blood pressure at baseline (SBP ≥ 140 mmHg and/or DBP ≥ 90 
mmHg) (Fig. 4b). 
The safety and tolerability of rimonabant 20 mg has been reported previously in the individual studies [21-24]; 
pooled safety results are presented in Table 3. Briefly, rimonabant 20 mg was generally well tolerated, with the 
safety data consistent in different subpopulations; the most common adverse events, occurring in at least 5% of 
patients and more commonly with rimonabant 20 mg than placebo, were upper respiratory tract infection, 
nausea, influenza, dizziness, diarrhoea, asthenia/fatigue, anxiety and insomnia. The percentage of patients 
experiencing adverse events which led to study discontinuation was similar in both the overall patient population 
and those patients wit high blood pressure at baseline (Table 3a). Specifically, adverse events leading to study 
discontinuation in the overall population occurred in 7.2 and 13.8% of patients in the placebo and rimonabant 20 
mg groups, respectively, in year 1, the most common of which are listed in Table 3b. 
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(a) Analysis of covariance: relationship between change in weight from baseline and change in systolic blood pressure (SBP) (left panel) and 
diastolic blood pressure (DBP) (right panel) at 1 year in the overall intention-to-treat (ITT) population from the four pooled RIO studies. For 
graphical display purposes, patients in each treatment group were divided according to decile of weight change, and mean change in blood 
pressure and weight were calculated for each decile. Results are presented as mean (SEM) for the ITT population, (b) Analysis of covariance: 
relationship between change in weight from baseline and change in SBP (left panel) and DBP (right panel) at 1 year in patients with high 
blood pressure at baseline in the four pooled RIO studies (high blood pressure defined as SBP ≥ 140mmHg and/or DBP ≥ 90mmHg in 
patients without type 2 diabetes and SBP ≥ 130mmHg and/or DBP ≥ 85mmHg in patients with type 2 diabetes). Dotted lines and solid 
squares, placebo; solid lines and solid triangles rimonabant 20 mg. 
 
DISCUSSION 
In the individual RIO trials and the pooled data, small but consistent decreases in both SBP and DBP were 
observed following 1 year of treatment with rimonabant 20 mg/day. This relatively small reduction was observed 
despite normal mean blood pressure at baseline; however, in the subset of patients with elevated blood pressure 
at baseline, more pronounced reductions in both SBP and DBP were noted and both were reduced significantly 
more by rimonabant 20 mg compared with placebo treatment. It is also relevant to note that the total blood 
pressure-lowering effect does not include the 1-4 mmHg reductions in blood pressure observed during the 4-
week run-in period in these trials. These results are consistent with the blood pressure reductions observed in 
hypertension prevention trials in patients with normal or high blood pressure [13]. Current clinical evidence 
indicates that blood pressure elevation above optimal levels (i.e. > 115/75 mmHg) will increase an individual's 
risk of developing cardiovascular diseases [2,27]. Thus, even small reductions in blood pressure from above 
optimal levels should impart a health benefit, especially in the overweight/obese population [28]. 
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(a) Changes in systolic blood pressure (SBP) (left panel) and diastolic blood pressure (DBP) (right panel) at 1 year in the subset of patients 
with type 2 diabetes at baseline. Data are means from the intention-to-treat (ITT) population. Between-group comparisons are least-squares 
mean differences (SEM) (P versus placebo), (b) Changes in SBP (left panel) and DBP (right panel) at 1 year in the subset of patients with 
type 2 diabetes and high blood pressure at baseline (high blood pressure defined as SBP ≥ 130mmHg and/or DBP ≥ 85 mmHg in patients 
with type 2 diabetes). Type 2 diabetes (RIO-Diabetes) defined as haemoglobin A1c 6.5-10.0% and fasting glucose concentration 5.55-15.04 
mmol/l, as per protocol. White bars, placebo; black bars rimonabant 20 mg. 
 
Among the individual trials, the reductions in blood pressure were somewhat more evident in the studies which 
specifically  enrolled  patients  at  higher cardiometabolic risk (e.g. patients with dyslipidaemia or type 2 
diabetes). The small antihypertensive effect in the overall patient population adds to the other, previously 
reported, cardiometabolic benefits of rimonabant; namely, reduced body weight and waist circumference, 
improved lipid profile (higher HDL-C and lower TG), reduced C-reactive protein and improved glycaemic 
control [21-24]. Since risk factors tend to cluster within individuals, improvements in multiple inter-related 
parameters is a reasonable approach to reducing overall cardiometabolic risk [29]. 
Cardiovascular outcomes trials of antihypertension therapy have established that small differences in systolic 
blood pressure reductions (2-4 mmHg) are associated with large reductions (10-20%) in major cardiovascular 
events [3]. It is also interesting to note that in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), for 
example, in which two antihypertensive regimens were compared (amlodipine plus perindopril as required 
versus atenolol plus bendroflumethiazide and potassium as required), differential systolic reductions in SBP and 
DBP of 2.8 and 1.9mmHg, respectively, were associated with a 14% reduction in risk of fatal coronary heart 
disease (GHD), non-fatal myocardial infarction and coronary revascularizations [30]. Moreover, further analyses 
of these trial results indicated that blood pressure differences alone could not account for differences in 
outcomes, and that small beneficial effects on other risk factors, including HDL-G, TG, HbAlc and fasting blood 
glucose appeared to contribute to the reduced risk in coronary events [30]. 
The effect of rimonabant 20 mg/day on blood pressure seems to be mediated by weight loss, with rimonabant 
having no apparent direct effect on blood pressure at the dose of 20 mg/day beyond that attributable to weight 
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loss. In contrast, approximately half of the improvements in HDL-C, TG and HbAlc levels produced by 




(a) Changes in systolic blood pressure (SBP) (left panel) and diastolic blood pressure (DBP) (right panel) at 1 year in the subset of patients 
with untreated dyslipidaemia at baseline. Data are means from the intention-to-treat (ITT) population. Between-group comparisons are least-
squares mean differences (SEM) (P versus placebo), (b) Changes in SBP (left panel) and DBP (right panel) at 1 year in the subset of patients 
with untreated dyslipidaemia and high blood pressure at baseline (high blood pressure defined as SBP ≥ 140mmHg and/or DBP ≥90mmHg). 
Dyslipidaemia defined as triglyceride levels ≥ 1.69mmol (150mg/dl) and/or total cholesterol/high-density lipoprotein cholesterol (HDL-C) 
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Table 3    Safety  
(a) Summary of adverse events at 1 year (pooled data from four RIO studies) 
 Placebo [n (%)] Rimonabant 20 mg [n (%)] 
Overall patient population 1602 2503 
Patients with any adverse event 1310 (81.8) 2152 (86.0) 
   Patients with diabetes, any adverse eventa 276/348 (79.3) 288/339 (85.0) 
   Patients with dyslipidaemia, any adverse eventb 279/342 (81.6) 300/346 (86.7) 
   Patients ≥ 65 years old, any adverse event 87/105 (82.9) 145/1 70 (85.3) 
   Men, any adverse event 380/477 (79.7) 542/652 (83.1) 
   Women, any adverse event 930/11 25 (82.7) 1610/1851  (87.0) 
   Patients with any serious adverse event 67 (4.2) 148 (5.9) 
Discontinuations due to adverse events 115 (7.2) 346 (13.8) 
Patients with high blood pressure at baselinec 401 532 
Patients with any adverse event 319 (79.6) 461  (86.7) 
Patients with any serious adverse event 1 8 (4.5) 41  (7.7) 
Discontinuations due to adverse events 29 (7.2) 70 (13.2) 
(b) Most common adverse events that led to discontinuationd
 Placebo [n (%)] Rimonabant 20 mg [n (%)] 
Patient population 1602 2503 
Any class, any event 115 (7.2) 346 (13.8) 
Depressive disorders* 13 (0.8) 48 (1.9) 
Nausea 2 (0.1) 34 (1.4) 
Mood alterations with depressive symptoms** 9 (0.6) 26 (1.0) 
Anxiety 5 (0.3) 26 (1.0) 
Dizziness 1  (<0.1) 1 7 (0.7) 
Pregnancy 0(0) 5 (0.5) 
(c) Adverse events (by system organ class and preferred term) occurring in ≥ 2% of patients in the rimonabant 
20 mg group and by ≥ 1 % compared with patients in the placebo group 
 Placebo [n (%)] Rimonabant 20 mg [n (%)] 
Patient population 1602 2503 
Gastrointestinal disorders 419 (26.2) 761  (30.4) 
   Nausea 79 (4.9) 299 (11.9) 
   Diarrhoea 77 (4.8) 157 (6.3) 
   Vomiting 36 (2.2) 100 (4.0) 
Nervous system disorders 360 (22.5) 643 (25.7) 
   Dizziness 79 (4.9) 187 (7.5) 
   Hypoaesthia 9 (0.6) 40 (1.6) 
Psychiatric disorders 217 (13.5) 622 (24.9) 
   Anxiety 39 (2.4) 140 (5.6) 
   Insomnia 51  (3.2) 134 (5.4) 
   Mood alterations with depressive symptoms 49 (3.1) 11 9 (4.8) 
   Depressive disorders 25 (1.6) 79 (3.2) 
   Irritability 9 (0.6) 48 (1.9) 
   Nervousness 4 (0.2) 29 (1.2) 
Miscellaneous   
   Upper respiratory tract infection 1 82 (11.4) 311  (12.4) 
   Asthenia/fatigue 80 (5.0) 151  (6.0) 
   Contusion 10 (0.6) 54 (2.2) 
   Tendonitis 1 6 (1.0) 52 (2.1) 
   Hot flush 1 2 (0.7) 47 (1.9) 
aRIO-Diabetes population. bRIO-Lipids population. cBlood pressure ≥ 140/90 mmHg (RIO-North America, RIO-Europe and RIO-Lipids) or 
≥ 130/85 mmHg (RIO-Diabetes) as per protocol. d Adverse events shown are those that occurred in at least 0.5% of patients in any treatment 
group (for preferred term) that led to discontinuation. * Includes: depression, dysthymic disorder and major depression according to the 
Medical Dictionary for Regulatory Activities (MedDRA). ** Includes: anhedonia, depressed mood, tearfulness and depressive symptoms 
according to MedDRA. Generally less severe than depressive disorders, with more transient symptoms and less therapeutic intervention. 
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It is difficult to separate the effect of weight loss itself from   concomitant   benefits   of  weight   loss,   such   as 
reductions in visceral fat, hyperinsulinaemia and insulin resistance [7,8], all of which may contribute to the 
observed blood pressure-lowering effect of rimonabant therapy. Substantial evidence implicates visceral obesity 
in the pathophysiology of obesity-related hypertension [5,31]. The visceral adipose tissue is an intriguing 
potential site for the effects of CB1 blockade, as recent studies in humans have shown increased CB1 receptor 
expression in visceral compared with subcutaneous adipose tissue, and higher endocannabinoid levels in obese 
patients with a predominance of visceral compared with subcutaneous excess adipose tissue [18,19]. In the RIO 
trials, reductions in abdominal obesity (as measured by waist circumference) paralleled body weight loss [21-
24]. 
Preclinical studies have shown that endogenous canna-binoids exert a hypotensive effect, particularly in rodent 
models of hypertension or under conditions of endotoxic or haemorrhagic shock [20,32]. CB1 agonists lower 
blood pressure much more in spontaneously hypertensive rats (SHR) than in normotensive Wistar-Kyoto rats, 
while CB1 blockade prevented this effect in SHR but had no effect on blood pressure in normotensive rats. These 
results suggest a role of the ECS in the regulation of blood pressure; however, it is important to note that the 
blood pressure-lowering effect of endocannabinoids in these hypertensive animal models is accounted for 
primarily by tonic suppression of cardiac contractility in hypertension, and that a pressor effect of CB1 blockade 
has only been noted in animal models of hypertension with supraphysiological doses and in anaesthetized but not 
conscious animals [20]. There is no evidence of any pressor effect of rimonabant in any clinical studies. Our data 
demonstrate that rimonabant treatment does not counteract the favourable effects of weight loss and of 
mobilization of abdominal fat on blood pressure in overweight/obese humans [13]. On the contrary, the RIO 
clinical data showed reductions in blood pressure with rimonabant therapy, which are more pronounced in 
patients with high blood pressure at baseline. 
There are several limitations in these analyses of the effects of rimonabant on blood pressure. First, the studies 
were not specifically designed to evaluate the effect of rimonabant in hypertension. For this reason, more 
rigorous methods for assessing blood pressure, such as use of an automated blood pressure recording system or 
ambulatory blood pressure measurements, were not employed. Second, both body weight and blood pressure 
decreased during the 4-week dietary run-in period; thus, the changes from randomization do not fully capture the 
total effects that may be seen in clinical practice. Large, randomized, controlled trials specifically designed to 
evaluate cardiovascular outcomes of long-term rimonabant therapy are currently ongoing. 
In summary, the results of this analysis demonstrate that treatment with rimonabant at 20 mg/day can lower the 
blood pressure of overweight/obese patients in addition to its effect on other cardiometabolic risk factors such as 
abdominal obesity, dyslipidaemia, inflammation, dysgly-caemia and insulin resistance. While the overall blood 
pressure-lowering effect of rimonabant was relatively small and was entirely attributable to the concomitant 
body weight loss, there was no evidence of blood pressure increases with rimonabant treatment. In patients with 
high blood pressure at baseline, improvements in SBP and DBP were more pronounced than in the overall 
pooled population. Taken collectively, the effects on blood pressure, plus the previously demonstrated 
improvements in lipid profile, glycaemic control and abdominal obesity, support the use of selective CB1 
blockade with rimonabant as a novel approach to the management of multiple cardiometabolic risk factors. 
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